Live news , top stories, corporate news, company news, sector news, economy news, results analysis news, ceo interviews, fund manager interview, advisor interview, market news, bazaar talk, hot stocks news, ipo news, commodities news, mutual fund news, insurance news, news wire
27 April, 2018 04:29 IST
Lupin receives USFDA nod for generic Seroquel XR tablets
Source: IRIS | 19 May, 2017, 08.20AM
Comments  |  Post Comment

Pharma Major Lupin announced today that it has received final approval for its Quetiapine Fumarate Extended-Release Tablets, 50 mg, 150 mg, 200 mg, 300 mg and 400 mg from the United States Food and Drug Administration (FDA) to market a generic version of AstraZeneca Pharmaceuticals LP's Seroquel XR Tablets 50 mg, 150 mg, 200 mg, 300 mg and 400 mg.

Lupin's Quetiapine Fumarate Extended-Release Tablets, 50 mg, 150 mg, 200 mg, 300 mg and 400 mg are the AB rated generic equivalent of AstraZeneca Pharmaceuticals LP's Seroquel XR Tablets 50 mg, 150 mg, 200 mg, 300 mg and 400 mg.

It is indicated for the treatment of schizophrenia; acute manic or mixed episodes in bipolar I disorder alone or as an adjunct to lithium or divalproex; acute depressive episodes in bipolar disorder; maintenance treatment of bipolar I disorder, as an adjunct to lithium or divalproex and as an adjunctive therapy to antidepressants for the treatment of major depressive disorder.

Seroquel XR Extended-Release Tablets had US sales of USD 1.27 billion (IMS MAT March 2017).

Shares of the company gained Rs 7.85, or 0.61%, to trade at  Rs 1,304.90.  The total volume of shares traded  was  67,273 at the BSE (4.01 p.m., Thursday).



Lupin Limited   (Q,N,C,F)*

Comments Post comment 
 Post Comment
Name Email
Comment
Security Code type    into this box
Related Articles
Thermax wins Rs 2.79 bn order for captive cogeneration plant - 26-Apr-2018 16:52
Yes Bank Q4 net jumps 29% to Rs 11.79 bn - 26-Apr-2018 15:25
Supreme Industries quarterly net up 32% - 26-Apr-2018 13:48
Infratel-Indus merger reflects India telco cash pressure: Fitch - 26-Apr-2018 13:44
Infratel-Indus merger reflects India telco cash pressure: Fitch - 26-Apr-2018 13:44
Indiabulls Real Estate quarterly profit zooms 23.69 times - 26-Apr-2018 12:49
Indoco gets UK health regulators nod to supply critical products - 26-Apr-2018 10:05
Zydus receives final approval from USFDA to market 2 drugs - 26-Apr-2018 09:36
Wipro Q4 earnings fall 6.7% q-o-q to Rs 18 bn - 25-Apr-2018 16:23
Sterlite Technologies quarterly profit surges 77% - 25-Apr-2018 15:42
Reliance Nippon Life Asset Management Q4 profit rises 35% to Rs 1.62 bn - 25-Apr-2018 15:34
more...
Home  |   Shares  |   F&O  |   Mutual Funds  |   Loans  |   Insurance  |   News Centre
Wealth Tracker  |   Newsletters  |   Tax Corner  |   NRI Centre  |   Advertise
© All rights reserved. IRIS Business Services Limited
A Disclaimer